Patents by Inventor Jordan M. Chinai

Jordan M. Chinai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
    Publication number: 20210388052
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: January 4, 2021
    Publication date: December 16, 2021
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
    Patent number: 10882893
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 5, 2021
    Assignee: Albert Einstein College of Medicine
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
    Publication number: 20190263886
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: March 13, 2019
    Publication date: August 29, 2019
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
    Patent number: 10280208
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 7, 2019
    Assignee: Albert Einstein College of Medicine
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser
  • TMIGD2 AND ITS DERIVATIVES AS BLOCKERS OR BINDERS OF CANCER-EXPRESSED HHLA2 FOR IMMUNOTHERAPIES
    Publication number: 20170174742
    Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
    Type: Application
    Filed: April 24, 2015
    Publication date: June 22, 2017
    Inventors: Xingxing Zang, Jordan M. Chinai, Murali Janakiram, Steven C. Almo, Andras Fiser